NASDAQ: BSGMBiosig Technologies Inc Stock
$1.63+0.12 (+7.95%)
Updated Apr 17, 2024
BSGM Price
$1.63
Fair Value Price
-$0.04
Market Cap
$18.25M
52 Week Low
$0.26
52 Week High
$16.50
P/E
-0.41x
P/B
-6.05x
P/S
1,940.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.00k
Earnings
-$29.04M
Gross Margin
100%
Operating Margin
-161,338.89%
Profit Margin
-161,388.9%
Debt to Equity
-1.55
Operating Cash Flow
-$17M
Beta
1.08
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BSGM Overview
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BSGM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BSGM ($1.63) is overvalued by 4,159.1% relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BSGM ($1.63) is not significantly undervalued (4,159.1%) relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BSGM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BSGM due diligence checks available for Premium users.
Be the first to know about important BSGM news, forecast changes, insider trades & much more!
BSGM News
Valuation
BSGM fair value
Fair Value of BSGM stock based on Discounted Cash Flow (DCF)
Price
$1.63
Fair Value
-$0.04
Undervalued by
4,159.10%
BSGM ($1.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BSGM ($1.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BSGM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BSGM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
28.84x
Market
41.64x
BSGM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.05x
Industry
3.66x
BSGM's financial health
Profit margin
Revenue
$12.0k
Net Income
-$6.0M
Profit Margin
-50,425%
BSGM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BSGM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8M
Liabilities
$4.7M
Debt to equity
-1.55
BSGM's short-term liabilities ($4.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BSGM's short-term assets ($528.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BSGM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BSGM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$4.0k
Financing
$2.7M
BSGM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BSGM vs Medical Device Stocks
Biosig Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.